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Chronic myeloid leukemia (CML) is a myeloproliferative disorder in which neoplastic cells exhibit the Philadelphia chromosome
and the related oncoprotein BCR-ABL1. Allogeneic stem cell transplantation (allo-SCT) was considered the first-line treatment for
CML, before the introduction of tyrosine kinase inhibitors (TKIs). However, patients are at risk for relapse years after trans-
plantation. We present a patient who relapsed 25 years after allo-SCT for chronic phase CML. Polymerase chain reaction (PCR)
detected gradually evaluated levels of BCR-ABL1 transcripts, eventually leading to the diagnosis of relapsed disease. Additional
mutational analyses did not reveal mutations in the BCR-ABL1 gene, or other cooperating mutations.*e patient was successfully
treated with imatinib 400mg daily, leading to new molecular remission. *e case presentation emphasizes the need for long-term
follow-up of such patients and the potential benefit of initiating TKI treatment with early signs of relapse.
1. Introduction
Nearly 1.5 million people worldwide suffer from chronic
myeloid leukemia (CML), which is morphologically char-
acterized by an accumulation of myeloid precursor cells in
the peripheral blood and bone marrow. Philadelphia
chromosome-positive CML is identified by the genetic
translocation t(9;22)(q34;q11.2) [1], with the fusion of the
Abelson (ABL1) oncogene with the breakpoint cluster region
(BCR) gene. *e malignant transformation is hence caused
by the acquisition of the constitutively active tyrosine kinase
BCR-ABL1 in a hematopoietic stem cell, transforming it into
a leukemic stem cell (LSC) that self-renews, proliferates, and
differentiates to give rise to a myeloproliferative neoplastic
disease [2, 3]. CML LSCs are believed to evolve as a result of
both epigenetic and genetic events and to divide less
frequently, representing a reservoir for relapsed and re-
sistant disease [2, 3].
Since the introduction of tyrosine kinase inhibitors
(TKIs), targeting the kinase activity of BCR-ABL1, CML has
transformed from a once fatal to a manageable disease for
the vast majority of patients [4]. However, before the in-
troduction of TKIs, the only potential curative treatment
offering hope of long-time survival was allogenic stem-cell
transplantation (allo-SCT) [5], although associated with
high rates of treatment-related mortality and morbidity.
Most patients who relapsed after allo-SCT would do so
within the first year after transplant, although later relapses
have also been described [6–9]. Here, we present a patient
relapsing 25 years after initial allo-SCTof CML, emphasizing
the importance of long-time follow-up for allo-transplanted
patients.
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2. Case Presentation
A previously healthy 41-year-old woman was diagnosed with
CML, after presentation of symptoms caused by hyper-
splenism with gravity sensation under the right costal
margin. Initial blood tests demonstrated severe leukocytosis
227×109/L (normal range 4–11× 109/L) together with in-
creased serum concentration of lactate dehydrogenase
(LDH) 969U/L (200–450U/l) and cobalamin 2834 pmol/L
(150–840 pmol/L). A blood smear demonstrated dominance
of myeloid precursor with increased metamyelocytes and
rods. CML was conrmed by identication of the Phila-
delphia chromosome t(9; 22) by using conventional
G-banding analyses.
Treatment was initiated with hydroxyurea combined
with interferon, and the patient reached morphological
remission, then proceeded to allo-SCT for consolidation
treatment. e transplantation was performed by a mye-
loablative condition (MAC) regime with busulphan 1mg/kg
for four days followed by cyclophosphamide 60mg/kg for
two days, followed by bone marrow-derived stem cell from
her human leukocyte antigen- (HLA-) matched sister.
Standard graft versus host disease (GVHD) prophylaxis by
using cyclosporine A andmethotrexate on day 1, 3, 6, and 11
after transplant was given [10]. No severe complications
were observed after transplant, and especially, she did not
develop any signs of acute or chronic GVHD.
After the development of polymerase chain reaction
(PCR) analysis for BCR-ABL1 transcripts [11], this test has
been regarded as mandatory in the follow-up of CML pa-
tients [11]. Six years after the allo-SCT, an e13a2 transcript of
BCR-ABL1 was detected by nested PCR. She was therefore
controlled twice yearly, without signs of progression judged
from karyotyping and interphase uorescence in situ hy-
bridization (FISH) of 200 interphases with probes against
BCR and ABL1 in the bone marrow. By standardization of
quantitative real-time (RT) PCR, yearly analyses were per-
formed [11], and low but detectable transcript levels were
still observed, although molecular remission (MR) levels
were below MR3.
Her transcript levels then suddenly increased rapidly,
and she lost her MR (Figure 1). is was conrmed by
analysis at two di¡erent laboratories. e patient proceeded
to bone marrow examination showing normal metaphases
by G-banding and only one cell with BCR-ABL1 of 245
interphases by FISH using dual fusion probes, and this was
regarded as insignicant. e bone marrow smear was
hypercellular with increased myeloid precursors and
megakaryocytes, although without evidence of increased
myeloblasts. Hence, we maintained the diagnosis of CML
with molecular relapse appearing 25 years after initial allo-
SCT. e patient was screened for other mutations com-
monly occurring in myeloid malignancies, including mu-
tations in BCR-ABL1, but no additional mutations were
detected. Donor chimerism status revealed that the majority
of myeloid cells (99%) were of donor origin.We thought that
her relapsed disease was likely to be sensitive to treatment
with rst-generation TKI, and she was given imatinib
400mg daily. She tolerated the treatment well without major
side e¡ects; after three months, she obtained MR4 status
(Figure 1), and imatinib treatment was continued with
regular monitoring of BCR-ABL1 quantitative RT-PCR.
3. Discussion
Allo-SCT played a central role in CML treatment before the
TKIs era because it was the only treatment with proven
curative potential [5]. For this reason, CML was the most
common indication for allo-SCT until the beginning of the
new millennium. e susceptibility of CML to the graft-
versus-leukemia (GVL) e¡ect, the documented e¡ect of
donor lymphocyte infusion (DLI) in CML relapse, and the
possibility to monitor minimal residual disease (MRD) were
features placing this disease at the forefront of allo-SCT
research. However, the introduction of imatinib, and the
clearly therapeutic benets of this treatment approach, led to
a rapid decline of the transplantation rates in CML. How-
ever, several patients successfully transplanted for CML are
still under follow-up worldwide. Most CML relapses after
allo-SCT occurred during the rst year after transplant,
although late relapses, including extramedullary relapses can
also be detected [6–9,12–15].
e present patient was allografted before the in-
troduction of TKIs. She was given induction therapy with
hydroxyurea and interferon, considered as the standard
treatment at that time [16]. After receiving a complete
morphological remission, she was allografted with an HLA-
matched sibling donor. During the posttransplant follow-up,
she had persistent detection of BCR-ABL1 transfusion
transcripts. e method of detecting BCR-ABL1 transcripts
has been standardized more recently [11]; hence, an accurate
quantitative measurement of BCR-ABL1 transcripts has
been available only the last years before the relapse (Fig-
ure 1). However, the patient had proven detection of BCR-
ABL1 transcript for >5 years before the posttransplant re-
lapse.e detection of such minimal residual disease (MRD)



















Figure 1: Development in BCR-ABL1/ABL1 transcript levels in the
setting of relapsed CML. e gure shows the BCR-ABL1/ABL1
transcript levels in peripheral blood for the patient. Time point
0 represents the diagnosis of CML relapse and initiating of imatinib
therapy.
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patients treated with TKIs [17]. *e detection of BCR-ABL1
transcripts is believed to be caused by the persistence of an
LSC pool in CML patients [2]. However, the clinical im-
portance or therapeutic implications of such MRD detection
is controversial, although a rapid increase in transcript levels
or loosing of previous MR should wake the attention from
the treating physician.
Studies have demonstrated that patients with BCR-ABL1
expression in the hematopoietic stem cell compartment
seem to have inferior survival irrespective of the disease
status [18]. *e quantitative RT-PCR has become widely
used for monitoring minimal residual disease after allo-SCT
for CML. However, most of these studies were performed
using qualitative RT-PCR, and the interpretation of the
results obtained has been conflicting. By the use of quan-
titative RT-PCR performed early within three to five years
after allo-SCT, a clear relationship between BCR-ABL1
transcript level and probability of relapse seem apparent
[19].
In the 1990s, donor lymphocyte infusion (DLI) was the
mainstay of treatment for posttransplant CML relapse
[20, 21]. DLI induced durable responses in 60–70% of pa-
tients relapsing with chronic phase CML [21], whereas
durable remissions in patients relapsing into accelerated or
blast phase are less frequent [21]. *e main obstacle in
allografted patients is GVHD that can be a very sever
complication. On the other hand, GVHD seems to be highly
correlated to response rates [21, 22]. TKIs are now accepted
as the preferred alternative for treating CML relapse after
allo-SCT [23–25]. TKIs can induce complete cytogenetic
responses (CCRs) and deep molecular response (MR), even
in patients failing DLI, and the treatment is without risk of
GVHD [26–28]. Early identification of altered intracellular
signaling may be a predictor of response to TKI therapy [29],
although whether this is evident also in patients relapsing
after allo-SCT remains elusive.
BCR-ABL1 kinase domain point mutations are detect-
able in approximately 50% of patients with treatment failure
and progression on TKIs, although the incidence of BCR-
ABL1mutations in patients relapsing after allo-SCTremains
uncertain. Although our patient had not been exposed to
TKIs previously, we considered this as a relapsed disease.We
therefore investigated her for BCR-ABL1mutations, but this
could not be detected. Hence, treatment with imatinib was
initiated. No clinical studies comparing different TKIs in
CML relapse after allo-SCT exist, and the choice of TKI
should in our opinion be based on risk for potential side
effects, patient age, previous exposure to TKI, and potential
BCR-ABL1 mutations.
*e use of maintenance TKI treatment after allo-SCT has
also been investigated [30–33] and seems to be well-tolerated
with a low risk for GVHD [30–33]. TKIs have the potential
for changing the kinetics of the disease and should probably
be recommended for CML patients allo-grafted [33, 34], also
in the advanced phase of the disease [33, 34]. Maintenance
therapy may not be required for patients that achieve full
donor chimerism and deep MR [25].
To conclude, our case report emphasizes the need for
long-time follow-up for allo-transplanted CML patients.
Despite stable levels of BCR-ABL1 transcripts over years,
relapse can still occur. Early diagnostics and introduction of
TKI therapy are crucial to avoid transformation to more
advanced stage of CML.
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